Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcus Biosciences (RCUS) Liabilities and Shareholders Equity (2017 - 2026)

Arcus Biosciences has reported Liabilities and Shareholders Equity over the past 9 years, most recently at $1.1 billion for Q4 2025.

  • For Q4 2025, Liabilities and Shareholders Equity fell 0.96% year-over-year to $1.1 billion; the TTM value through Dec 2025 reached $4.3 billion, down 12.24%, while the annual FY2025 figure was $1.1 billion, 0.96% down from the prior year.
  • Liabilities and Shareholders Equity for Q4 2025 was $1.1 billion at Arcus Biosciences, up from $974.0 million in the prior quarter.
  • Over five years, Liabilities and Shareholders Equity peaked at $1.6 billion in Q4 2021 and troughed at $839.3 million in Q3 2021.
  • A 5-year average of $1.2 billion and a median of $1.2 billion in 2023 define the central range for Liabilities and Shareholders Equity.
  • Biggest five-year swings in Liabilities and Shareholders Equity: skyrocketed 430.88% in 2021 and later fell 25.08% in 2025.
  • Year by year, Liabilities and Shareholders Equity stood at $1.6 billion in 2021, then dropped by 18.34% to $1.3 billion in 2022, then dropped by 15.77% to $1.1 billion in 2023, then rose by 5.02% to $1.2 billion in 2024, then decreased by 0.96% to $1.1 billion in 2025.
  • Business Quant data shows Liabilities and Shareholders Equity for RCUS at $1.1 billion in Q4 2025, $974.0 million in Q3 2025, and $1.1 billion in Q2 2025.